KR0156747B1 - Use of 1,3-oxathiolan nucleoside analogues in the treatment of hepatitis-b - Google Patents

Use of 1,3-oxathiolan nucleoside analogues in the treatment of hepatitis-b Download PDF

Info

Publication number
KR0156747B1
KR0156747B1 KR1019930701998A KR930701998A KR0156747B1 KR 0156747 B1 KR0156747 B1 KR 0156747B1 KR 1019930701998 A KR1019930701998 A KR 1019930701998A KR 930701998 A KR930701998 A KR 930701998A KR 0156747 B1 KR0156747 B1 KR 0156747B1
Authority
KR
South Korea
Prior art keywords
hepatitis
treatment
nucleoside analogues
oxathiolan
oxathiolan nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019930701998A
Other languages
English (en)
Korean (ko)
Inventor
Nghe Nguyen-Ba
Bernard Belleau
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR0156747(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919100039A external-priority patent/GB9100039D0/en
Priority claimed from GB919109913A external-priority patent/GB9109913D0/en
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Application granted granted Critical
Publication of KR0156747B1 publication Critical patent/KR0156747B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
KR1019930701998A 1991-01-03 1993-07-02 Use of 1,3-oxathiolan nucleoside analogues in the treatment of hepatitis-b Expired - Lifetime KR0156747B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919100039A GB9100039D0 (en) 1991-01-03 1991-01-03 Medicaments
GB919109913A GB9109913D0 (en) 1991-05-07 1991-05-07 Medicaments

Publications (1)

Publication Number Publication Date
KR0156747B1 true KR0156747B1 (en) 1998-11-16

Family

ID=26298202

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930701998A Expired - Lifetime KR0156747B1 (en) 1991-01-03 1993-07-02 Use of 1,3-oxathiolan nucleoside analogues in the treatment of hepatitis-b

Country Status (23)

Country Link
US (2) USRE39155E1 (cg-RX-API-DMAC7.html)
EP (2) EP0565549B1 (cg-RX-API-DMAC7.html)
JP (1) JP2659863B2 (cg-RX-API-DMAC7.html)
KR (1) KR0156747B1 (cg-RX-API-DMAC7.html)
AT (1) ATE120644T1 (cg-RX-API-DMAC7.html)
AU (1) AU660650B2 (cg-RX-API-DMAC7.html)
CA (2) CA2254613A1 (cg-RX-API-DMAC7.html)
CY (1) CY2047B1 (cg-RX-API-DMAC7.html)
DE (1) DE69201948T2 (cg-RX-API-DMAC7.html)
DK (1) DK0565549T3 (cg-RX-API-DMAC7.html)
EE (1) EE02995B1 (cg-RX-API-DMAC7.html)
ES (1) ES2070628T3 (cg-RX-API-DMAC7.html)
GE (1) GEP19981482B (cg-RX-API-DMAC7.html)
GR (1) GR3015694T3 (cg-RX-API-DMAC7.html)
HK (1) HK159395A (cg-RX-API-DMAC7.html)
IE (1) IE73642B1 (cg-RX-API-DMAC7.html)
IL (1) IL100502A (cg-RX-API-DMAC7.html)
MD (1) MD1224C2 (cg-RX-API-DMAC7.html)
NO (1) NO180407C (cg-RX-API-DMAC7.html)
PH (1) PH31397A (cg-RX-API-DMAC7.html)
TJ (1) TJ249B (cg-RX-API-DMAC7.html)
TW (1) TW202385B (cg-RX-API-DMAC7.html)
WO (1) WO1992011852A1 (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
US5932635A (en) * 1991-07-30 1999-08-03 Cytec Technology Corp. Tackified prepreg systems
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
AU7954694A (en) * 1993-09-10 1995-03-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
JP3047045B2 (ja) * 1994-10-22 2000-05-29 チョン クン ダン コーポレーション ヌクレオシド誘導体およびその製造方法
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6689761B1 (en) 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
GB9517022D0 (en) * 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
GB9605293D0 (en) * 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments
KR20000022226A (ko) 1996-06-25 2000-04-25 그레이엄 브레레톤;레슬리 에드워즈 Hiv 치료에 사용하기 위한 vx478, 지도부딘, ftc 및(또는) 3tc를 포함하는 배합물
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
CA2285577A1 (en) 1997-04-07 1998-10-15 Triangle Pharmaceuticals, Inc. Compositions containing mkc-442 in combination with other antiviral agents
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6395716B1 (en) 1998-08-10 2002-05-28 Novirio Pharmaceuticals Limited β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
IL142910A0 (en) * 1998-11-02 2002-04-21 Triangle Pharmaceuticals Inc Combination therapy to treat hepatitis b virus
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
ATE383355T1 (de) 2001-03-01 2008-01-15 Abbott Lab Polymorph und andere kristallinische formen von zusammen-ftc
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-c-메틸-3'-o-l-발린에스테르 리보푸라노실 사이티딘
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
SI1572095T1 (sl) 2002-09-13 2015-12-31 Novartis Ag Beta-l-2'-deoksinukleozidi za uporabo pri zdravljenju odpornih sevov hbv
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
US7598373B2 (en) 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
US7781576B2 (en) 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
WO2010137027A1 (en) 2009-05-27 2010-12-02 Hetero Research Foundation Solid oral dosage forms of lamivudine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT82580B (pt) * 1985-05-15 1989-01-17 Wellcome Found Processo para a preparacao de 2',3'- didesoxinucleosidos e de composicoes farmaceuticas que os contem
CA1327000C (en) * 1987-08-07 1994-02-15 David L.J. Tyrrell Antiviral therapy for hepatitis b
US5039667A (en) * 1987-08-07 1991-08-13 The Governors Of The University Of Alberta Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
JP2578501B2 (ja) * 1989-03-03 1997-02-05 キヤノン株式会社 電子写真用帯電部材
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
JPH04501854A (ja) * 1989-05-15 1992-04-02 アメリカ合衆国 肝炎の治療方法
EP0472663A4 (en) * 1989-05-15 1992-07-01 Us Commerce Method of treatment of hepatitis
ATE183508T1 (de) * 1989-06-27 1999-09-15 Wellcome Found Therapeutische nukleoside
IE902574A1 (en) * 1989-07-17 1991-02-27 Univ Birmingham Antiviral pyrimidine nucleosides
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
KR910007655A (ko) * 1989-10-03 1991-05-30 엠. 피. 잭슨 치료용 뉴클레오시드
IE74701B1 (en) * 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
PT95516A (pt) * 1989-10-06 1991-08-14 Wellcome Found Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
JP2960164B2 (ja) * 1990-11-13 1999-10-06 バイオケム ファーマ インコーポレイテッド 抗ウイルス特性を有する置換1,3−オキサチオラン類および置換1,3−ジチオラン類
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
GB9105899D0 (en) * 1991-03-20 1991-05-08 Wellcome Found Therapeutic nucleosides
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments

Also Published As

Publication number Publication date
NO932442L (no) 1993-08-26
USRE39155E1 (en) 2006-07-04
JP2659863B2 (ja) 1997-09-30
MD1224C2 (ro) 1999-11-30
CY2047B1 (en) 1998-04-30
CA2100269C (en) 1999-02-23
NO180407B (no) 1997-01-06
IL100502A0 (en) 1992-09-06
AU1153492A (en) 1992-08-17
EP0565549B1 (en) 1995-04-05
MD1224B2 (en) 1999-05-31
GEP19981482B (en) 1998-12-25
DE69201948T2 (de) 1995-08-03
ATE120644T1 (de) 1995-04-15
DE69201948D1 (de) 1995-05-11
ES2070628T3 (es) 1995-06-01
WO1992011852A1 (en) 1992-07-23
DK0565549T3 (da) 1995-07-03
CA2254613A1 (en) 1992-07-04
CA2100269A1 (en) 1992-07-04
TW202385B (cg-RX-API-DMAC7.html) 1993-03-21
TJ249B (en) 1999-12-23
IE920004A1 (en) 1992-07-15
AU660650B2 (en) 1995-07-06
PH31397A (en) 1998-10-29
NO180407C (no) 1997-04-16
MD950086A (ro) 1997-01-31
EE02995B1 (et) 1997-06-16
IL100502A (en) 1995-12-08
NO932442D0 (no) 1993-07-05
EP0494119A1 (en) 1992-07-08
EP0565549A1 (en) 1993-10-20
GR3015694T3 (en) 1995-07-31
HK159395A (en) 1995-10-20
JPH06507150A (ja) 1994-08-11
IE73642B1 (en) 1997-06-18
US5532246A (en) 1996-07-02

Similar Documents

Publication Publication Date Title
CY2047B1 (en) Use of 1,3-oxathiolane nucleoside analogues in the manufacture of a medicament for treatment of hepatitis B
HUT59109A (en) Process for producing hydroxymethyl-(methylenecyclopentyl)-purines and -pyrimidines, their pharmaceutically acceptable salts and pharmaceutical compositions comprising same
IL101144A0 (en) Pharmaceutical compositions containing 1,3-oxathiolane nucleoside analogue and derivatives thereof for the treatment of hepatitis b virus infections
GR3018915T3 (en) Antiviral combinations containing nucleoside analogs
IL88755A (en) (1:, 2, 3:)-3-substituted-2- hydroxycyclo- butanemethanol derivatives and pharmaceutical and veterinary compositions containing the same
HU910681D0 (en) Medical solution
GR3005990T3 (cg-RX-API-DMAC7.html)
GR3024028T3 (en) Cytotoxic and antiviral compound.
CY1870A (en) Derivatives of penciclovir for the treatment of hepatitis-B infections
IL88740A0 (en) Compositions for the inhibition of viruses
DK0855398T3 (da) Sesquiterpenderivater med antiviral aktivitet
AU1662092A (en) Use of a 1,3-oxathiolan derivative for the treatment of hepatitis b infection
ZA927307B (en) Method for treating hypertension
TW275629B (cg-RX-API-DMAC7.html)
PH30180A (en) Leustroducsin h its preparation and its therapeutic use

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19930702

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19951006

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19930702

Comment text: Patent Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19980608

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19980724

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19980724

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20010718

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20020708

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20030707

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20040709

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20050711

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20060711

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20070710

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20080701

Start annual number: 11

End annual number: 11

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Patent event code: PJ02062R01D

Patent event date: 20081014

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 19980724

Comment text: Registration of Establishment

Decision date: 20090128

Request date: 20081014

Appeal identifier: 2008100003065

Appeal kind category: Confirmation of the scope of right_affirmative

J301 Trial decision

Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_AFFIRMATIVE REQUESTED 20081014

Effective date: 20090128

PJ1301 Trial decision

Patent event code: PJ13011S02D

Patent event date: 20090128

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Appeal kind category: Confirmation of the scope of right_affirmative

Request date: 20081014

Decision date: 20090128

Appeal identifier: 2008100003065

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Decision date: 20090609

Request date: 20090130

Appeal identifier: 2009100000198

Appeal kind category: Confirmation of the scope of right_affirmative

Decision date: 20090609

Request date: 20090130

Appeal identifier: 2009100000197

Appeal kind category: Confirmation of the scope of right_affirmative

Patent event code: PJ02062R01D

Patent event date: 20090130

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 19980724

Comment text: Registration of Establishment

Decision date: 20090609

Request date: 20090130

Appeal identifier: 2009100000195

Appeal kind category: Confirmation of the scope of right_affirmative

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

Appeal identifier: 2009100000198

Request date: 20090130

Appeal kind category: Confirmation of the scope of right_affirmative

Decision date: 20090609

Appeal identifier: 2009100000197

Request date: 20090130

Appeal kind category: Confirmation of the scope of right_affirmative

Decision date: 20090609

Patent event code: PJ12011R01D

Patent event date: 20090609

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2009100000195

Request date: 20090130

Appeal kind category: Confirmation of the scope of right_affirmative

Decision date: 20090609

PR1001 Payment of annual fee

Payment date: 20090708

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20100719

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20110617

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20120628

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20120628

Start annual number: 15

End annual number: 15

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20131022

Termination category: Expiration of duration